logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Taselisib for PIK3CA-mutant HR+ advanced breast cancer lacks clinical utility in SANDPIPER

Phase 3 trial found modest efficacy but safety problems.